FDA's showdown with Grassley to delay nomination

Acting FDA commissioner Andrew von Eschenbach is refusing to turn over information on the antibiotic Ketek to Senator Charles Grassley. According to von Eschenbach, giving the senator everything he asked for would make it difficult for the agency to conduct independent investigations. From Grassley's perspective, the FDA is not being compliant with a subpoena. It all adds up to a further delay for von Eschenbach's nomination, which is now being blocked by Grassley, a powerful Republican senator who has often been harshly critical of drug companies as well as the FDA.

- read the Washington Post report on the showdown

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.